[Real-life utilization of fixed triple therapy in COPD: The Trilife study. Beclomethasone/formoterol/glycopyrronium triple fixed-dose therapy in extra-fine particles].

Autor:	Roche N; Pneumologie, hôpital Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France. Electronic address: nicolas.roche@aphp.fr., Bernady A; Pneumologie, centre médical cardio-respiratoire Toki Eder, Cambo-les-Bains, France., Piperno D; Pneumologie, centre médical Parot, Lyon, France., Bachiri A; Chiesi, Bois-Colombes, France., Fiocca J; Chiesi, Bois-Colombes, France., Lardy-Cléaud A; RCTs, Lyon, France., Lafargue S; RCTs, Lyon, France., Guillemin S; RCTs, Lyon, France., Devillier P; VIM Suresnes-UMR-0892, université Paris Saclay, hôpital Foch, Suresnes, France.
Jazyk:	francouzština
Zdroj:	Revue des maladies respiratoires [Rev Mal Respir] 2024 Dec; Vol. 41 (10), pp. 715-726. Date of Electronic Publication: 2024 Nov 01.
DOI:	10.1016/j.rmr.2024.10.003
Abstrakt:	Introduction: The Trilife study describes the real-life use, in France, of the beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in solution for inhalation, which is indicated as continuous treatment for moderate-to-severe chronic obstructive pulmonary disease. Methods: This prospective, non-interventional, multicentric study, involving hospital and office-based pulmonologists, evaluates the proportion of patients for whom the triple fixed combination was prescribed in compliance with the indication and dosage specified in the summary of product characteristics (SPC). Patients were followed for six months. Results: In a population of 346 patients, the prescription was compliant with the SPC for 75.1% of patients (95% confidence interval: [70.6; 79.7]). The only variable associated with compliance with SPC in multivariate analyses was smoking (P=0.019). The results also show improved patient adherence to treatment and improved clinical status in terms of moderate or severe exacerbations, dyspnea, quality of life and satisfaction with treatment. Conclusion: Three quarters of the fixed triple combination prescriptions by French pulmonologists comply with the indication and dosage specified in the summary of product characteristics. (Copyright © 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu